Document is current
Any future updates will be listed below
-
Authors
Rothwell, Joseph A. https://orcid.org/0000-0002-6927-3360
Bešević, Jelena
Dimou, Niki
Breeur, Marie
Murphy, Neil
Jenab, Mazda
Wedekind, Roland
Viallon, Vivian
Ferrari, Pietro
Achaintre, David
Gicquiau, Audrey
Rinaldi, Sabina
Scalbert, Augustin
Huybrechts, Inge
Prehn, Cornelia
Adamski, Jerzy
Cross, Amanda J.
Keun, Hector
Chadeau-Hyam, Marc
Boutron-Ruault, Marie-Christine
Overvad, Kim
Dahm, Christina C.
Nøst, Therese Haugdahl
Sandanger, Torkjel M.
Skeie, Guri
Zamora-Ros, Raul
Tsilidis, Kostas K.
Eichelmann, Fabian
Schulze, Matthias B.
van Guelpen, Bethany
Vidman, Linda
Sánchez, Maria-José
Amiano, Pilar
Ardanaz, Eva
Smith-Byrne, Karl
Travis, Ruth
Katzke, Verena
Kaaks, Rudolf
Derksen, Jeroen W. G.
Colorado-Yohar, Sandra
Tumino, Rosario
Bueno-de-Mesquita, Bas
Vineis, Paolo
Palli, Domenico
Pasanisi, Fabrizio
Eriksen, Anne Kirstine
Tjønneland, Anne
Severi, Gianluca
Gunter, Marc J.
- License Information
-
More Information
Article History
Received: 8 November 2022
Accepted: 16 January 2023
First Online: 28 February 2023
Declarations
:
: Approval for the EPIC study was obtained from the International Agency for Research on Cancer (IARC) and local center review boards. All participants provided written informed consent. The two colorectal cancer case-control studies were approved by the ethics committee at the International Agency for Research on Cancer (IARC) on 7 April 2014 (IEC 14-08). For the UK Biobank, ethical approval was obtained from the North West Multicentre Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. Ethical approval for the cohort was most recently renewed in 2021 by the National Health Service (NHS) Health Research Authority in 2021 (21/NW/0157). All participants provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
